Eli Lilly (LLY) Enters Research Collaboration with BioArctic AB
Eli Lilly and Company has entered a research collaboration agreement with BioArctic AB to develop a potential new treatment for neurodegeneration. The deal includes an upfront payment of $30 million, up to $770 million in milestone payments, and tiered royalties on future sales.
Tickers: $LLY